US 12,404,242 B2
Compositions and methods for making and using small molecules in the treatment of cancer
Vijay Gokhale, Houston, TX (US); and Teri C. Suzuki, Houston, TX (US)
Assigned to Reglagene, Inc., Houston, TX (US)
Appl. No. 18/718,991
Filed by Reglagene, Inc., Houston, TX (US)
PCT Filed Dec. 16, 2022, PCT No. PCT/IB2022/062416
§ 371(c)(1), (2) Date Jun. 12, 2024,
PCT Pub. No. WO2023/111996, PCT Pub. Date Jun. 22, 2023.
Claims priority of provisional application 63/291,144, filed on Dec. 17, 2021.
Prior Publication US 2025/0109105 A1, Apr. 3, 2025
Int. Cl. C07D 213/643 (2006.01); A61K 31/426 (2006.01); A61K 31/44 (2006.01); A61K 31/505 (2006.01); C07D 239/34 (2006.01); C07D 277/34 (2006.01)
CPC C07D 213/643 (2013.01) [A61K 31/426 (2013.01); A61K 31/44 (2013.01); A61K 31/505 (2013.01); C07D 239/34 (2013.01); C07D 277/34 (2013.01)] 3 Claims
 
1. A compound according to formula (I),

OG Complex Work Unit Chemistry
or formula (II),

OG Complex Work Unit Chemistry
wherein:
R1 and R6 are each independently selected from the group consisting of:

OG Complex Work Unit Chemistry
R2 is selected from the group consisting of CH3 or F;
wherein R3 and R7 are each a 5- or 6-membered heteroaryl unsubstituted or optionally substituted with one or more groups independently selected from the group consisting of alkyl, alkylamino, halogen, alkylhalide, cyano, cycloalkyl, heterocyclic alkyl, aryl, heteroaryl, cycloalkoxyl, heterocyclic alkoxyl, cycloalkylthio, and heterocyclic alkylthio,
R4 and R5 are each independently selected from the group consisting of H and F; and
R8 is selected from the group consisting of CH3 and H.